How Are We Addressing Axial Psoriatic Arthritis in Clinical Practice?

Autor: Michelena X; Rheumatology, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. xabier.michelena@vallhebron.cat., López-Medina C; Rheumatology, Maimónides Institute for Biomedical Research of Córdoba (IMIBIC)University of CordobaReina Sofía University Hospital, Córdoba, Spain., De Miguel E; Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain., Moreno-Ramos MJ; Rheumatology, Virgen de la Arrixaca University Hospital, El Palmar, Murcia, Spain., Queiro R; Rheumatology, Faculty of Medicine, Asturias University Hospital, Sección de inmunología traslacional del instituto de investigación sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain., Marzo-Ortega H; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Juanola X; Rheumatology, Bellvitge University Hospital, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Rheumatology and therapy [Rheumatol Ther] 2024 Dec; Vol. 11 (6), pp. 1441-1456. Date of Electronic Publication: 2024 Oct 18.
DOI: 10.1007/s40744-024-00722-w
Abstrakt: Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the musculoskeletal system, skin and nails. In addition to peripheral joints, inflammation of the spine and sacroiliac joints may occur. Yet, research into this axial phenotype has lagged behind partly because of the challenge in its clinical identification with a lack of specific clinical, molecular or imaging biomarkers. In the absence of a validated definition of what constitutes axial PsA (axPsA), guidelines for the management of axial involvement in PsA in clinical practice are scarce. On the basis of a literature review and their clinical expertise, a group of rheumatology experts provide their opinion to aid the diagnosis and management of axial PsA in clinical practice.
Competing Interests: Declarations Conflict of Interest Xabier Michelena has received speaking fees and honoraria as advisor from: Abbvie, Janssen, Lilly, Novartis and UCB. Clementina López Medina has received honoraria as speaker fees/consulting from: Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB. Eugenio De Miguel has received research funding/consulting and conferences fees from: Abbvie, Novartis, Roche, Pfizer, Janssen, Lilly, MSD, BMS, UCB, Grunental and Sanofi. Manuel José Moreno Ramos has received unrelated honoraria or research grants from Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer and UCB, and advisor´s honoraria from Abbvie, Janssen, Lilly, Novartis, Pfizer and UCB unrelated to the present work. Rubén Queiro has received honoraria as a panellist, consultant, speaker and researcher from: Abbvie, Celgene-Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. Helena Marzo-Ortega has received grant support from Janssen, Novartis, Pfizer and UCB. Honoraria and/or speaker fees from AbbVie, Amgen, Biogen, Eli-Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB. Xavier Juanola has received honoraria as a panellist, consultant, speaker or researcher from Abbvie, Lilly, MSD, Novartis, Pfizer and UCB. Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje